Physician profile
Jesus Ramirez
NPI 1871522201
$34,091.52
in general payments reported to CMS, 2019-2025
29 companies · $2,346 in 2025
The $2,346 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $1,529 · 2021: $25K · 2022: $1,235 · 2023: $1,225 · 2024: $1,616 · 2025: $2,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,099 · Education: $86.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,098.79 |
| Education | $86.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apria Healthcare LLC | $24,190.00 | 2021 | |
| Glaxosmithkline, LLC. | $2,930.62 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Inspire Medical Systems, INC. | $1,713.25 | 2022-2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $1,598.98 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $795.61 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Philips North America LLC | $663.38 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Genzyme Corporation | $473.96 | 2019-2025 | |
| Grifols USA, LLC | $279.48 | 2019-2021 | |
| Verona Pharma, INC. | $193.05 | 2025 | Ohtuvayre |
| Insmed, INC. | $173.79 | 2024-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $163.65 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $147.87 | 2022-2024 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $147.56 | 2019-2025 | Dupixent |
| Viatris Specialty LLC | $147.41 | 2025 | Yupelri |
| Mylan Specialty L.P. | $135.45 | 2023-2024 | Yupelri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $72.88 | 2019-2020 | |
| 3b Medical, INC. | $43.21 | 2024 | Luna |
| Fisher & Paykel Healthcare INC | $31.20 | 2020-2021 | |
| Allergan, INC. | $26.00 | 2019-2020 | |
| Amgen INC. | $22.01 | 2025 | Tezspire |
| Baxter Healthcare | $21.38 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $18.68 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.34 | 2022 | |
| Gilead Sciences, INC. | $15.90 | 2022 | |
| Olympus America INC. | $15.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.09 | 2020 | |
| Medtronic, INC. | $13.94 | 2025 | Illumisite |
| Intuitive Surgical, INC. | $12.76 | 2025 | |
| Abbvie INC. | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.